Diagnostic and prognostic testing for Solid Tumours

The Bristol Genetics Laboratory offers an expanding repertoire of molecular and cytogenetic tests for a range of solid tumour types, useful for confirming diagnosis, assessing prognosis and for guiding therapeutic decisions. This stratified or personalised medicine approach is important in the treatment and management of patients with solid tumours. Our laboratory offers state-of-the-art clinical molecular testing for a range of clinically actionable genes in a variety of tumour types.

Lung Cancer

  •  Lung cancer NGS panel (EGFR, BRAF, PIK3CA, KRAS and ERBB2)
  •  ALK FISH analysis


  • Melanoma gene panel (BRAF, KIT, NRAS, GNA11 and GNAQ)
  • BRAF codon 600 mutation analysis by pyrosequencing

Colorectal Cancer

  • Colorectal gene panel (KRAS, NRAS and BRAF)
  • MSI analysis
  • BRAF codon 600 mutation analysis by pyrosequencing
  • MLH1 promoter hypermethylation analysis


  • GIST gene panel (KIT, PDGFRA, BRAF, KRAS and NRAS)

Brain Tumours

  • MGMT promoter methylation analysis
  • 1p and 19q co-deletion analysis
  • IDH1 codon 132 and IDH2 codon 172 sequence analysis
  • H3F3A codon 28 and 35 and HIST1H3B codon 28 sequence analysis
  • BRAF codon 600 mutation analysis by pyrosequencing
  • BRAF fusion RT-PCR and FISH analysis
  • EGFR amplification FISH analysis
  • MYC FISH analysis
  • MYCN FISH analysis

For further information regarding any of these tests please see the Test List for Oncology Genomics Services or contact the laboratoryFor requesting please use the Molecular Pathology Request Form (download : Microsoft Office document icon Molecular Pathology Request Form Bristol Genetics Laboratory FM342.pdf ) or Neuropathology Request Form (download : PDF icon Neuropathology Request Form: Bristol Genetics Lab )  as appropriate.

Last Updated 29th July 2019